In:
Cancer Research, American Association for Cancer Research (AACR), Vol. 81, No. 4_Supplement ( 2021-02-15), p. PS6-40-PS6-40
Abstract:
Background:Clinical risk criteria (CRC) has been used in two well-known gene-expression trials (TAILORX and MINDACT) to predict the risk of distant recurrence (DR). The definition of clinical low-risk patients was (1) node-negative associated with (grade 1 with tumor ≤3cm, grade 2 with tumor≤2cm, or grade 3 with tumor ≤1cm) and N1 with grade 1 and tumor ≤2cm. Recurrence Index for distant recurrence (RI-DR) is a clinical-genomic model, based on genomic profiling derived from Asian women. The primary purpose of this study is to access the clinical utility of RI-DR and CRC in Asian breast cancer patients. Methods:A total of 208 patients (N0 70.2%, N1 29.8%) with luminal-like breast cancer were enrolled in a retrospective study across Taiwan medical centers. Kaplan-Meier method was used to calculate the survival rates and the log rank test was applied for the survival difference between two or more independent groups. The primary endpoint was the recurrence-free interval (RFI). Results:With a median follow-up of 49.05 [IQR 29.72-71.96], the 5-year RFI was significantly poorer in the high-risk group than the low-risk group (87.2% [95% CI, 80.0-95.0] versus 95.2% [89.75-100] by the RI-DR, p = 0.011; and 86.9% [79.8-94.6] versus 97.0% [92.9-100] by the clinical risk, p = 0.03). Combined the CRC and RI-DR together, clinical high (CH) and RI-DR high (RH)had the poorest 5-year RFI (85.2%, [76.6-94.8] ); clinical low (CL) and RI-DR low (RL) had the best 5-year RFI (98.0% [94.08, 100]). Among CL-risk patients, RL group has a trend towards less recurrence than RH group (1/66 [1.51%] versus 2/19 [10.52%], p= 0.15). Similar trend was observed in CH-risk patients (RL: 2/41 (4.88%) versus RH: 12/82 [14.63%] , p = 0.17) (Table 1). Conclusions:The present study provides robust evidences that clinical-risk criteria and RI-DR testing could partition patients into good and poor prognosis in early-stage luminal breast cancer. RI-DR has a trend to identify low- and high-risk patients if clinical risk criteria have been applied in clinical practice. Analyses of Clinical Risk Criteria and Recurrence Index TogetherNo. of PatientsNo. of Events5-year RFI % (95% CI)Log rank, P valueClinical-Clinical-HighRI-DR high821285.20 [76.55, 94.81]0.17RI-DR low41291.30 [80.15, 100] Clinical-LowRI-DR high19294.12 [83.57, 100]0.15RI-DR low66197.96 [94.08, 100] Citation Format: Skye Hung-Chun Cheng, Liang-Chih Liu, Ling-Ming Tseng, Chuan-Hsun Chang, Chiun-Sheng Huang, Ji-An Liang, Yu-Chen Hsu, Chia-Ming Hsieh, Jun-Ru Wei. Clinical risk criteria and recurrence index for distant recurrence for patients with early stage luminal breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS6-40.
Type of Medium:
Online Resource
ISSN:
0008-5472
,
1538-7445
DOI:
10.1158/1538-7445.SABCS20-PS6-40
Language:
English
Publisher:
American Association for Cancer Research (AACR)
Publication Date:
2021
detail.hit.zdb_id:
2036785-5
detail.hit.zdb_id:
1432-1
detail.hit.zdb_id:
410466-3
